Formula I GPR52 Modulators for Broad Neurological Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for improved GPR52 modulator compounds to treat various neurological conditions, as existing modulators are not sufficiently effective.
Innovation Solution
Development of compounds of Formula (I) and their pharmaceutically acceptable salts, which modulate the activity of GPR52 receptors, thereby treating neurological disorders such as schizophrenia, Parkinson's disease, and Alzheimer's disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing GPR52 modulators are used, then some therapeutic effect is achieved, but the effectiveness is insufficient for treating neurological conditions
Solution Approach 1:
The patent modifies chemical parameters of GPR52 modulator compounds by varying substituents at different positions (R1-R10) on the core molecular structure. This systematic parameter change approach generates compounds with optimized binding affinity and efficacy across multiple neurological conditions, resolving the contradiction between therapeutic effectiveness and broad adaptability
Solution Approach 2:
The patent develops a series of compounds that can universally target GPR52 receptors involved in multiple neurological disorders including schizophrenia, Parkinson's disease, Alzheimer's disease, and Huntington's disease. The modular molecular design allows single compounds or combinations to address diverse neurological conditions, achieving both high effectiveness and broad versatility
2Reliability
If new GPR52 modulator compounds are developed to improve effectiveness, then therapeutic benefits increase, but compound complexity increases
Solution Approach 1:
The patent segments the GPR52 modulator molecules into distinct functional modules: a core structure (Formula I) with variable substituent positions (R1-R10). This segmentation allows systematic optimization of each module's contribution to binding affinity and efficacy while maintaining overall structural coherence, balancing effectiveness with manageable complexity
Solution Approach 2:
The patent applies local quality by introducing specific substituents at targeted positions on the molecular structure to enhance interactions with specific regions of the GPR52 receptor. This localized optimization improves therapeutic effectiveness without requiring complete redesign of the entire molecular structure, thus controlling complexity
Data Source
AI summary
The present disclosure relates to compounds of Formula (I) that modulate the activity of G-protein coupled receptor 52 (GPR52), pharmaceutically acceptable salts of compounds of Formula (I), and pharmaceutical compositions thereof. Compounds, pharmaceutical salts of compounds, and pharmaceutical compositions of the present disclosure are directed to methods useful in the treatment or prophylaxis of a neurological disease or disorder and conditions related thereto.